Membranous Nephropathy Market Research Report - Forecast to 2023

Membranous Nephropathy Market Research Report: Type (Primary, Secondary) Treatment (Conservative Therapy, Non-Immunosuppressive Therapy) Diagnosis (CT Scan, Urine Test, Blood Test) End User (Hospitals, Specialty Centers) – Global forecast till 2023

Market Scenario

Membranous nephropathy is a kidney disorder. It is an autoimmune disorder which can occur by itself or in conjunction with several other diseases. Membranous nephropathy is one of the most common causes of the nephrotic syndrome. Membranous nephropathy can be caused due to various factors such as any autoimmune disease, use of certain medications such as nonsteroidal anti-inflammatory drugs, and exposure to certain infection such as hepatitis B, hepatitis C, and syphilis.

The global membranous nephropathy market is majorly driven by the growing prevalence of kidney disorders, rising older population leading to rise in the patient population, the rise in hepatitis affected infections, and growing mass young population inclined towards a sedentary lifestyle. Additionally, government funding’s, rising demand for novel treatment and market players offering advanced products are likely to drive the market.

According to the United Nations, in 2017 approximately over 962 million population were aged over 60 and above globally. United Nations has also estimated that by 2050, the number of older population is likely to reach 425 million. Additionally, according to WHO, around 71 million people are affected with hepatitis C globally. This rising aging population and rising hepatitis cases are likely to propel the growth of the global membranous nephropathy market. Factors that are likely to hamper the growth of the market are the lack of awareness regarding treatment.

The global membranous nephropathy market is expected to grow at a CAGR of 3.5% during the forecast period.

Figure: Global Membranous Nephropathy Market, by Region, 2016 (%)
Intended Audience

- Pharmaceutical Manufacturers and Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors

Research Methodology:

- Interviews and cold calls with KOL
  from demand and supply side of market
- Quantitative Primary Surveys
- Demand side includes doctors, general physicians, and other medical professionals
- Supply side includes manufacturers, wholesalers, retailers

Segments

The global membranous nephropathy market is segmented on the basis of type, treatment, diagnosis, and end-user.

On the basis of type, the market is segmented into primary and secondary.
On the basis of treatment, the market is segmented into conservative therapy, non-immunosuppressive therapy, and immunosuppressive therapy.

On the basis of diagnosis, the market is segmented into urine test (urinalysis), blood test, glomerular filtration rate test, an antinuclear antibody test, kidney ultrasound or Computed Tomography (CT), kidney biopsy, an anti-PLA2R antibody test, and others.

On the basis of end-user, the market is segmented into research centers, hospitals, and specialty centers.

Regional Analysis

The North American membranous nephropathy market is a growing market. On a regional basis, the Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. Increasing number of hepatitis affected the population, along with rising older population is likely to drive the market. Additionally, growing healthcare expenditure and rising demand for technologically advanced treatments and products along with the rising government support are likely to enhance the growth of the membranous nephropathy market in North America.

Europe is the second largest market and holds a healthy share in the global membranous nephropathy market. The European market is expected to grow at a healthy CAGR during the forecast period owing to the availability of newer and advanced treatment facilities and rising skilled medical professionals along with the growing need for a better healthcare scenario. Furthermore, rising older population, along with growing inclination towards sedentary lifestyle are driving the growth of the membranous nephropathy market.

Asia Pacific is expected to be the fastest growing market. Increasing prevalence of chronic diseases and infections are the major drivers for the market growth. China is the fastest growing region owing to an increasingly older population and rising patient population. Rising awareness regarding health and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and rise in the standard of living are driving the growth of the membranous nephropathy market in the Asia Pacific region.

The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access, and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market owing to the rise in healthcare development and rising demand for availability of specialty care centers.

Key Players

Some of the key players in the membranous nephropathy market are Abbvie, Inc., Allergan Plc., Amgen Inc., Astrazeneca Plc, F. Hoffmann-La Roche Ltd, and FibroGen, Pfizer Inc., among others.
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

6. Global Membranous Nephropathy Market, by Type
6.1 Introduction
6.2 Primary Membranous Nephropathy
6.2.1 Market Estimates & Forecast, 2017–2023
6.3 Secondary Membranous Nephropathy
6.3.1 Market Estimates & Forecast, 2017–2023

7. Global Membranous Nephropathy Market, by Diagnosis
7.1 Introduction
7.2 Urine Test (Urinalysis)
7.2.1 Market Estimates & Forecast, 2017–2023
7.3 Blood Tests
7.3.1 Market Estimates & Forecast, 2017–2023
7.4 Glomerular Filtration Rate Test
7.4.1 Market Estimates & Forecast, 2017–2023
7.5 Antinuclear Antibody Test
7.5.1 Market Estimates & Forecast, 2017–2023
7.6 Kidney Ultrasound or Computed Tomography (CT)
7.6.1 Market Estimates & Forecast, 2017–2023
7.7 Kidney Biopsy
7.7.1 Market Estimates & Forecast, 2017–2023
7.8 Anti-PLA2R Antibody Test
7.9 Others
7.9.1 Market Estimates & Forecast, 2017–2023

8. Global Membranous Nephropathy Market, by Treatment
8.1 Introduction
8.2 Conservative Therapy
8.2.1 Market Estimates & Forecast, 2017–2023
8.3 Non-Immunosuppressive Therapy
8.3.1 Market Estimates & Forecast, 2017–2023
8.4 Immunosuppressive Therapy
8.4.1 Market Estimates & Forecast, 2017–2023

9. Global Membranous Nephropathy Market, by End-U.S.er
9.1 Introduction
9.2 Hospitals
9.2.1 Market Estimates & Forecast, 2017–2023
9.3 Specialty Centers
9.3.1 Market Estimates & Forecast, 2017–2023
9.4 Research Centers
9.4.1 Market Estimates & Forecast, 2017–2023

10 Global Membranous Nephropathy Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 U.K.
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa

11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments

12 Company Profiles
12.1 Abbvie, Inc
LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for Global Membranous Nephropathy Market
Figure 3 Segmentation Market Dynamics for Membranous Nephropathy Market
Figure 4 Global Membranous Nephropathy Market Share, by Treatment 2016
Figure 5 Global Membranous Nephropathy Market Share, by Diagnosis 2016
Figure 6 Global Membranous Nephropathy Market Share, by End-User, 2016
Figure 7 Global Membranous Nephropathy Market Share, by Region, 2016
Figure 8 North America Membranous Nephropathy Market Share, by Country, 2016
Figure 9 Europe Membranous Nephropathy Market Share, by Country, 2016
Figure 10 Asia Pacific Membranous Nephropathy Market Share, by Country, 2016
Figure 11 Middle East & Africa Membranous Nephropathy Market Share, by Country, 2016
Figure 12 Global Membranous Nephropathy Market: Company Share Analysis, 2016 (%)
Figure 13 Abbvie, Inc: Key Financials
Figure 14 Abbvie, Inc: Segmental Revenue
Figure 16 Abbvie, Inc: Geographical Revenue
Figure 17 Allergan Plc: Key Financials
Figure 18 Allergan Plc: Segmental Revenue
Figure 19 Allergan Plc: Geographical Revenue
Figure 20 Amgen Inc.: Key Financials
Figure 21 Amgen Inc.: Segmental Revenue
Figure 22 Amgen Inc. Geographical Revenue
Figure 23 FibroGen: Key Financials
Figure 24 FibroGen: Segmental Revenue
Figure 25 FibroGen: Geographical Revenue
Figure 26 GlaxoSmithKline plc: Key Financials
Figure 27 GlaxoSmithKline plc: Segmental Revenue
Figure 28 GlaxoSmithKline Plc. Geographical Revenue
Figure 29 Ardelyx, Inc.: Key Financials
Figure 30 Ardelyx, Inc.: Segmental Revenue
Figure 31 Ardelyx, Inc.: Geographical Revenue
Figure 32 Astellas Pharma Inc.: Key Financials
Figure 33 Astellas Pharma Inc.: Segmental Revenue
Figure 34 Astellas Pharma Inc.: Geographical Revenue

marketresearchfuture.com / Phone (US) +1-646-845-9349 (UK) +44 208 133 9349